Cancer, neurodegeneration, cardiovascular disease, and metabolic dysfunction share upstream mechanisms. Agemica organizes around healthspan - preserved function and independence - not vanity charts.
“Aging is the highest-leverage disease driver we can address systematically.”
-
01
Evidence & replication
Programs are judged by mechanism-level evidence and whether results replicate beyond a single assay. Hypotheses are ranked before capital commits-experiments exist to collapse uncertainty.
-
02
Endpoints & oncology
Endpoints tie to function and resilience where possible; surrogates only when clearly justified. The near-term emphasis is cancer because regulatory and clinical paths still move indication by indication.
-
03
Claims & platform
Stage-appropriate claims only-preclinical work stays labeled as such until gates are met. The same platform stack applies as datasets widen.
Science, execution, and boundaries.
01 / 03
Discovery
Computational layers propose candidates and prioritize mechanisms; biological systems decide what survives. Breadth of evidence matters as much as a single headline number.
Execution
Peptide and vaccine programs advance when design–build–test loops stay short: clear protocols, traceable samples, and honest postmortems when models fail.
Evidence gates
External-facing milestones map to internal decision points-what would change our mind, what would stop a program, and what has to be true before the next tranche of work.
Capital should flow to ranked hypotheses, not to noise.